1. Scrip
  2. >>R&D

Argos And Agenus Trials Pile On Fresh Cancer Vaccine Disappointments

 
• By Emily Hayes

Argos mum on details surrounding Phase III failure of rocapuldencel-T in kidney cancer, while Agenus distances itself from failed Phase II glioblastoma study of Prophage G-200 as an investigator-sponsored trial with a challenging design.

Human brain illustrated with millions of small nerves - Conceptual 3d render

Cancervaccine development has sustained yet more blows with the early termination of Argos Therapeutics Inc.'s pivotal trial of the dendritic vaccine rocapuldencel-T in metastatic kidney cancer and Agenus Inc.'s Prophage G-200 in a National Cancer Institute (NCI) Phase II study of glioblastoma, in both cases for futility due to unlikelihood of improving overall survival.

Argos' announcement came Feb. 22, when the company said that an independent data monitoring committee (IDMC) recommended during an interim analysis termination of the long-running, Phase III ADAPT study, which tested the combination of rocapuldencel-T (AGS-003) with Pfizer Inc.'stargeted drug Sutent (sunitinib) against Sutent alone in 462 patients with metastatic renal cell carcinoma. Argos fell 66.5% to $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

More from Scrip

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.